WO2011033356A1 - Composición farmacéutica para bajar de peso y procedimiento para obtener la misma - Google Patents
Composición farmacéutica para bajar de peso y procedimiento para obtener la misma Download PDFInfo
- Publication number
- WO2011033356A1 WO2011033356A1 PCT/IB2010/002270 IB2010002270W WO2011033356A1 WO 2011033356 A1 WO2011033356 A1 WO 2011033356A1 IB 2010002270 W IB2010002270 W IB 2010002270W WO 2011033356 A1 WO2011033356 A1 WO 2011033356A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- orlistat
- pharmaceutical composition
- further characterized
- diluent
- carnitine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention is related to the techniques used in the pharmaceutical industry, and more particularly, it is related to a pharmaceutical composition for weight loss comprising as active ingredients Orlistat and L-Carnitine, as well as the process for obtaining it. BACKGROUND OF THE INVENTION
- Obesity has become one of the greatest threats to the population due to its increasing incidence and its ability to induce chronic pathologies in almost all body systems. In the last fifteen years, progress has been made in understanding the disease that exceeds those achieved during the previous one hundred years, this has created a rational basis for new therapies capable of preventing or reversing obesity.
- obesity Due to its magnitude and significance, obesity is considered in Mexico as a Public Health problem, as evidenced by the National Health Survey of the year 2000, detecting that from an early age there is a high prevalence of overweight and obesity, since that in adolescents there is 29% overweight and obesity and, in relation to adults, in women aged 20-59, 36.1% were overweight and 28.1% obese and, in men in the same group, 40.9 % overweight and 18.6% obese.
- obesity and overweight have detrimental effects on health in the short and long term in pediatric age, including: psychiatric disorders, high blood pressure, dyslipidemia, hypertrophy of the left ventricle, non-alcoholic steatohepatitis, alterations of endothelial function , hyperinsulinemia or insulin resistance, asthma, obstructive sleep apnea and orthopedic problems.
- psychiatric disorders high blood pressure, dyslipidemia, hypertrophy of the left ventricle, non-alcoholic steatohepatitis, alterations of endothelial function , hyperinsulinemia or insulin resistance, asthma, obstructive sleep apnea and orthopedic problems.
- Orlistat also known as tetrahydrolipostatin, is a drug to treat obesity, its main function is to prevent the absorption of fats from the human diet, thus reducing calorie intake. Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, dietary triglycerides are not hydrolyzed into absorbable acidic acids and are excreted without being digested. Its main effect is the local inhibition of lipase within the gastrointestinal tract after the consumption of this compound by an oral dose.
- L-Carnitine of its salts, the most commonly used is L-Carnitine tartrate (Ci 8 H 36 N20 12 ), (R) -Bis [ (3-carboxy-2-hydroxypropyl) trimethyl ammonium] L-tartrate, of formula (II)
- L-Carnitine Due to its role in lipid metabolism, L-Carnitine is used as an adjunct in the medical management of weight control in patients with exogenous obesity, due to excessive and disorderly food intake.
- composition created with the main objective of absorbing fat-soluble vitamins comprises a pancreatic lipase inhibitor such as Orlistat and L-Carnitine, each of them being administered from independently, that is, they are never mixed.
- a beneficial side effect in weight reduction was observed.
- the composition of said document uses a daily dose 50-300 mg of Orlistat and 50 to 8,000 mg of L-Carnitine.
- the document mentions a daily dose of 500 to 8,000 mg of L-Camitine in an adult.
- Orlistat was used in a daily dose of 360 mg using three capsules of 120 mg each, and for L-Carnitine, a daily dose of 1,000 mg was used before each of the three foods using an effervescent tablet, which added 3,000 mg per day, however this document does not mention the quantitative loss of weight observed, it only mentions a qualitative loss, but above all it does not show whether with amounts less than 3,000 mg of L -Carnitine per day a weight reduction is achieved.
- L-Carnitine Another document on L-Carnitine is that of Derosa G, Cicero AFG, GaddiA, Mugellini A, Ciccarelli L, Fogari R. "The Effect of L-carnitine on plasma lipoprotein (a) levéis in hipercholesterolemic patients with type 2 diabetes mellitas Clin Ther 2003; 25 (5): 1429-39 This document describes a double-blind study for 26 weeks involving 47 men and 47 women between 45 and 57 years and with a BMI (Body Mass Index) of 27.3 ⁇ 2.5 kg / m 2 A diet of 1,400 to 1,600 Kcal / day was prescribed for both groups. The intervention group received 2,000 mg / day of L-Carnitine No significant weight loss or differences between groups were observed end of the study
- Bipolar Disord 2006; 8: 503-507 describes a study of the effect of L-Carnitine in 60 obese subjects (49 women and 11 men). A loss of 1.9 kg and 0.9 kg was observed in the treatment group (15 mg / kg / day of L-Carnitine) and the control respectively, assuming patients weighing 70 kg more than 1050 mg per day are needed. L-Carnitine. However, the observed weight loss is not significant nor were differences observed in the two groups. This study was conducted for 26 weeks and included a restriction of 1,500 Kcal in the diet.
- Orlistat for example capsules
- these are prepared from powders obtained by dry mixing, wet granulation or dry granulation procedures.
- a suitable preparation method is needed that confers the Orlistat with suitable physical characteristics such as being a homogeneous and free flowing powder to make its handling simple in the manufacture of a pharmaceutical form produced on a large scale, for example , the capsules.
- an innovative procedure is required for the efficient management of Orlistat if it is combined with another active ingredient.
- L-Carnitine and Orlistat can be used mixed in a pharmaceutical composition for weight loss, and Moreover, it was found that, in the pharmaceutical composition of the present invention, it is not necessary to use amounts greater than 1,000 mg of L-Carnitine to achieve such an objective.
- the above is interpreted as a synergistic effect resulting from the association of Orlistat and L-carnitine, which results in a greater effect on weight loss compared to the administration of each of these ingredients separately.
- Another unexpected result is that only one daily dose is needed to achieve substantial weight loss.
- the pharmaceutical weight loss composition of the present invention is characterized in that it comprises a mixture of Orlistat and L-Carnitine as active ingredients or a pharmaceutically acceptable salt thereof; and, a pharmaceutically acceptable carrier, wherein, the composition comprises 300 to 1,000 mg of L-Carnitine and 40 to 140 mg of Orlistat.
- the Orlistat is adsorbed or coated with a diluent that allows the Orlistat to be handled properly.
- a diluent that allows the Orlistat to be handled properly.
- said diluent be water soluble, wherein said diluent is found crystallized on the Orlistat in order to coat it.
- the Orlistat adsorbs on said diluent.
- the composition is formulated to be administered orally, preferably a pharmaceutical form of a capsule is preferred.
- a method for preparing a pharmaceutical composition as defined above for this purpose a technique was developed that allows the Orlistat to be handled in an easy and practical way that allows it to be easily mixed with L-Carnitine, avoiding Orlistat's properties of being a fatty and sticky substance.
- the process of the present invention comprises the steps of: dry mixing the Orlistat with a water soluble diluent or a non-alcohol soluble diluent. Subsequently, a wetting of the mixture is performed and then a granulation thereof; then, the granule obtained from Orlistat is dried; Then, the dried Orlistat granule is screened and then mixed with L-Carnitine granules and the pharmaceutically acceptable carrier, after this step, as an optional step, this composition is taken to its final pharmaceutical form, preferably a capsule.
- a method of treatment for overweight or obesity which consists in administering to a human patient a therapeutically effective amount of the pharmaceutical composition of the present invention as indicated above and in the amounts indicated, where the administration is only once a day.
- a pharmaceutical composition as defined above for the preparation of a medicament useful in the treatment of overweight or obesity, wherein the medicament is dosed only once at day.
- Figure 1 is a graph showing the conditions of onset of patients involved in a first clinical study, patients having been classified into groups according to the specific treatment they received during the clinical study.
- Figure 2 is a graph showing the final conditions of the treatment groups of Figure 1, one of the groups having been treated with a preferred embodiment of the pharmaceutical composition of the present invention.
- Figure 3 is a graph showing the percentage of patients who, at the end of the treatment, returned to their normal weight in each group of the first clinical study.
- Figure 4 is a graph showing the percentage of patients who, at the end of the treatment, reduced their weight but were still classified as overweight in each group of the first clinical study.
- Figure 5 is a graph that shows the percentage of patients who, at the end of the treatment, reduced their weight but were still classified with grade 2 obesity in each group of the first clinical study.
- Figure 6 is a graph illustrating the average decrease in body mass index in patients of a second clinical study who were treated with the composition of the present invention.
- Figure 7 is a graph showing the reduction in body mass index achieved in patients treated in the second clinical study.
- a pharmaceutical composition comprising a mixture of Orlistat and L-Carnitine as active ingredients or a pharmaceutically acceptable salt thereof; and, a pharmaceutically acceptable carrier, wherein, the composition comprises 300 to 1,000 mg of L-Carnitine and 40 to 140 mg of Orlistat.
- the amounts used in the composition were shown to have a marked effect on weight reduction, above these limits an unnecessary amount would be supplied to achieve the desired effect and below that an amount that would not have an effect on the loss would be provided. of weight.
- the term "pharmaceutically acceptable” means a material compound or composition that, within the scope of the responsible medical criteria, is suitable for contact with the tissues of humans and animals without toxicity, irritation, allergic response or other excessive problematic complications according to a reasonable profit / risk ratio.
- the association and mixing of the active ingredients of the composition has greater effectiveness in weight loss compared to the use thereof individual way In other words, the active ingredients have a synergistic effect due to their association.
- the composition comprises 600 mg of L-Carnitine, and in another additional embodiment it comprises 120 mg of Orlistat. These amounts are appropriate in order to manufacture a pharmaceutical form of the composition of only one daily dose to reduce weight.
- the composition is most preferably formulated in a single oral dosage unit.
- the L-Carnitine salt used in the composition is L-Carnitine tartrate, although other salts such as levocarnitine, L-Carnitine fumarate, L-Carnitine orotate can be used.
- L-Carnitine tartrate is preferred because it is the salt that is most easily obtained in the market and facilitates providing L-Carnitine in greater proportion with respect to the other salts, in addition, it is more stable.
- Orlistat in the pharmaceutical composition, Orlistat is adsorbed or coated by a diluent which facilitates the process of obtaining the composition as will be seen a little later. More specifically, said diluent is soluble in water so that the Orlistat is coated by said diluent, which is selected from the group comprising maltose, isomalt, lactitol, sugar, mannitol and dextrose.
- Orlistat when Orlistat is adsorbed on the diluent, this is a diluent not soluble in an alcohol, for example an alcohol of 2 or 3 carbon atoms, such as ethyl alcohol or isopropyl alcohol.
- an alcohol for example an alcohol of 2 or 3 carbon atoms, such as ethyl alcohol or isopropyl alcohol.
- An example of a diluent with these characteristics is calcium phosphate.
- the pharmaceutical composition of the present invention be formulated for oral administration, preferring the form of a capsule, a tablet, an oral solution, a powder to reconstitute by adding a liquid, more preferably, it is preferred to formulate the composition in a capsule, which may well be a capsule made of either hard gelatin or soft gelatin, hydroxypropyl methyl cellulose capsules (HPMC) and pululan (NP capsules).
- the capsule contains a maximum of 15% of the pharmaceutically acceptable carrier in order to provide an adequate supply of the active ingredients.
- a dry mixing step of the Orlistat is performed with a water soluble diluent or a non-alcohol soluble diluent.
- this mixture is wetted and granulated; then, a drying step of the Orlistat granule is carried out and then a screening of this dry granule; Then, a dry mixture of the Orlistat with granules of the L-Carnitine and the pharmaceutically acceptable carrier is carried out, finally the mixture of these two active ingredients is taken to its final pharmaceutical form, preferably a capsule.
- a water soluble diluent preferably lactose, maltose, isomalt, lactitol, sugar, mannitol and dextrose is used in the dry mixing step of the Orlistat; preferably this dry mixing step is performed in a high speed mixer-granulator (High shear).
- the wetting step is preferably performed using purified water to form wet granules which are then screened by a rotor mill.
- the drying step of the wet granule of Orlistat can be performed in a fluidized bed, which preferably works at room temperature. Once the Orlistat granule has dried, sieving is carried out using a rotor mill, where there are no problems with melting or bonding of the Orlistat.
- the Orlistat granule is mixed with the L-Carnitine and the pharmaceutically acceptable carrier, which preferably comprises at least one moisture adsorbent or desiccant such as magnesium metasilicate aluminum, talc and silicon dioxide and, a Lubricant such as calcium stearate, zinc stearate, talc, sodium stearyl fumarate and magnesium stearate.
- the pharmaceutically acceptable carrier which preferably comprises at least one moisture adsorbent or desiccant such as magnesium metasilicate aluminum, talc and silicon dioxide and, a Lubricant such as calcium stearate, zinc stearate, talc, sodium stearyl fumarate and magnesium stearate.
- a granulate of the brittle, fragile and non-unctuous pharmaceutical composition is obtained, which does not present handling problems during encapsulation.
- the lactose is solubilized and when dried it causes the crystallization of the lactose on Orlistat, which causes that the characteristic property of Orlistat to be a fatty powder is not present, consequently, the final mixing of Orlistat with L-Carnitine is facilitated, and consequently the large-scale production of a capsule or other is facilitated Pharmaceutical forms of the composition of the present invention.
- the latter in the dry mixing stage of the Orlistat with the diluent, is characterized in that it is a non-soluble diluent in an alcohol of 2 or 3 carbon atoms such as the ethyl or isopropyl alcohol, the diluent can be calcium phosphate, or others that are not soluble in said alcohols, mixing can be carried out in a high-speed mixer-granulator (High shear).
- a high-speed mixer-granulator High shear
- isopropyl alcohol or ethyl alcohol is used, forming granules, then the sieving of the wet granulate of Orlistat is carried out by means of a rotor mill. Subsequently, the wet granule is dried, preferably at room temperature by a fluidized bed
- Orlistat's dry granule is screened by a rotor mill, without melting or sticking problems. Then, the final mixing of the Orlistat with the L-Carnitine is carried out, and the pharmaceutically acceptable vehicle comprising at least one moisture adsorbent or desiccant and a lubricant, this final mixture can be performed using a bins mixer. Finally, the composition is taken to its final pharmaceutical form by encapsulation without glue problems caused by the Orlistat.
- the modality where a water soluble diluent is used has the advantage of being an aqueous procedure without solvent exposure, while in the non-alcohol soluble diluent modality, it allows the density of the pharmaceutical composition is larger allowing the filling in capsule, for example a capsule of size 00 elongated (capacity of 1.02 milliliters). But it should be noted that both modalities are useful for obtaining the composition of the present invention.
- the wetting of the components with the humectant that can be water or an alcohol ensures that the components acquire the appropriate consistency that allows the formation of granules to be obtained Orlistat uniforms by sieving and drying.
- the wetting end point is achieved when taking a portion of a sample with your hand and pressing it gently, you get a firm dough that separates it in half and separates into two portions without completely fragmenting. When this occurs, wet sieving can be carried out to form a uniform Orlistat granule.
- the drying stage of the wet granulate of Orlistat an attempt is made to obtain a uniform moisture content and it is convenient to maintain an amount of residual moisture, so that the different components remain in a hydrated state, therefore it is necessary to carry out controls on the content of granulate moisture until the residual moisture specified for the composition is obtained.
- Temperature control is important to ensure the stability of the components subjected to granulation.
- the drying temperature is 35.0 ° C to 40.0 ° C and the residual humidity of the granule should not be greater than 1.0%.
- the particle size of the ingredients and carriers and diluents used in the composition be uniform, because particles of different dimensions tend to stratify at rest, movement or during transport, which results in an inaccurate dosage of the active ingredients.
- active ingredients and vehicles except magnesium stearate
- they are passed through 24 final mesh, which gives a particle size of approximately 701 microns.
- the Theological characteristics necessary to form for example a capsule with the composition are obtained.
- magnesium stearate this is passed through 60 mesh to create a smaller particle size and a larger surface area than the rest of the formulation thus favoring the lubrication of the product.
- Another important factor to take care of in the procedure is that because the mixtures of the two active ingredients carried out sequentially have a more homogeneous distribution of their components than the random mixtures, so it is necessary to be careful in the order in which the ingredients are placed and in the same way to verify the complete homogenization before adding the following component. Also, by setting mixing times and repeating each batch, the standardization of the process between different batches of the product is guaranteed.
- This control is required to prevent segregation or variation of the content of the active substance within the product. Mixing times and orders for adding raw materials are verified according to the manufacturing procedure.
- the relative humidity is within specification to avoid that said environmental factor influences the rheological behavior of the product thus affecting the encapsulation process. So periodic verification throughout the process, and this should not exceed 60% relative humidity, above this limit the higher relative humidity in the composition can be affected functionally with respect to its flow or valuation, therefore dehumidification measures should be taken in case The established specifications are exceeded.
- composition of the present invention is useful in the treatment of overweight and obesity in a human patient, for this purpose the composition is supplied in a therapeutically effective amount of the active ingredients as indicated above and only once per day, which It is highly practical, since patients prefer a single dose instead of multiple dosages per day.
- GELOIL glyceryl distearate and polyglyceryl-3-dioleate
- a pharmaceutical composition in capsule form was prepared in accordance with the ingredients and amounts mentioned in Table 8.
- a pharmaceutical capsule composition was prepared in accordance with the ingredients mentioned in Table 9.
- Orlistat 120 mg and Carnitine 600 mg associated with diet and exercise is more effective than the active ingredients separately Orlistat (OL) and L-Carnitine (CA), in reducing Weight administered orally, a clinical trial was performed with the following characteristics.
- BMI Body Mass Index
- pancreatic disorder Patients with suspected or diagnosed pancreatic disorder.
- Group A 20 overweight subjects, BMI from 25 to 29.9 kg / m 2
- Group B 20 subjects with grade 2 obesity, BMI of 30-39 kg / m 2
- Group C 20 subjects with grade 3 BMI obesity above 40 kg / m 2 .
- the age group prevailed between 18 and 30 years with 45.0%; the group of 31 to 40 years of age 25.0%; 41 to 50 years 15.0%; 51 to 60 years old 8.3% and the group from 61 to 70 years 6.6%.
- treatment groups were formed as follows:
- Figures 1 and 2 show the data at the beginning and end of the treatment.
- the evaluation was excellent in 80% (48/60) of the enrolled subjects, very good in 15% (9/60) Good in 5% (3/60).
- the average monthly weight loss was 2.4 ⁇ 2.3 kg, the results show statistically significant differences, the average weight at the end of the study was greater than 10% in the OL-CA group, non-significant weight losses were documented in the controlled groups. .
- the objective of the study was to demonstrate the clinical efficacy of the composition of the present invention by dosing it once a day, in the weight loss of 5% or more in the first 12 weeks of treatment and a weight loss of 10% in the second 12 weeks.
- Oral capsules one capsule every 24 hours, containing 60 mg of Orlistat and 600 mg of L-Carnitine tartrate.
- the overall average weight by age and sex was 84.1 kg ⁇ 1.1 kg; for the age group of 12 to 13 years, 70 ⁇ 1.3 Kg for the group of 13 to 14 years 80.2 ⁇ 1.5 kg for the group of 14 to 15 years 90. 5 ⁇ 1.1 kg and for the group of 15 to 16 years 100.7 ⁇ 1.6 kg (table 5) the average size was 172 ⁇ 15 cms. (Table 12).
- Table 12 Average weight of 60 patients by age and sex they received
- TOTAL 28 3 32 60 99.8% 94% of enrolled subjects performed approximately 1 hr a day of physical activity (sports in their schools) the remaining 6% performed at least 2 times per week extra physical activity to sports at their school.
- BMI decreased on average 5.3% in the first 12 weeks, in the second twelve weeks the reduction in BMI reached on average was statistically significant see Figure 6.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10816760.2A EP2478902A4 (en) | 2009-09-18 | 2010-09-13 | PHARMACEUTICAL COMPOSITION FOR WEIGHT REDUCTION AND METHOD FOR THE PRODUCTION THEREOF |
BR112012006013A BR112012006013A2 (pt) | 2009-09-18 | 2010-09-13 | composição farmacêutica para perda de peso e método para a produção da mesma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMX/A/2009/009971 | 2009-09-18 | ||
MX2009009971A MX342962B (es) | 2009-09-18 | 2009-09-18 | Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011033356A1 true WO2011033356A1 (es) | 2011-03-24 |
Family
ID=43758159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/002270 WO2011033356A1 (es) | 2009-09-18 | 2010-09-13 | Composición farmacéutica para bajar de peso y procedimiento para obtener la misma |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2478902A4 (es) |
AR (1) | AR078185A1 (es) |
BR (1) | BR112012006013A2 (es) |
CO (1) | CO6541522A2 (es) |
EC (1) | ECSP12011800A (es) |
GT (1) | GT201200079A (es) |
MX (1) | MX342962B (es) |
WO (1) | WO2011033356A1 (es) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998034607A1 (en) | 1997-02-05 | 1998-08-13 | F. Hoffmann-La Roche Ag | Tetrahydrolipstatin containing compositions |
WO2003009840A1 (en) * | 2001-07-24 | 2003-02-06 | Lonza Ag | Composition comprising at least one lipase inhibitor and carnitine |
WO2008082373A2 (en) * | 2006-12-29 | 2008-07-10 | Nobel Ilac San. Ve Tic. A.S. | Pharmaceutical formulations comprising lipase inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1305308B1 (it) * | 1999-03-26 | 2001-05-04 | Biosint S P A | Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione |
CN1546017A (zh) * | 2003-11-30 | 2004-11-17 | 杨喜鸿 | 奥利司他的复方制剂 |
JP2006191830A (ja) * | 2005-01-12 | 2006-07-27 | Unitika Ltd | 脂肪の蓄積を抑制する食品 |
SI2002825T1 (sl) * | 2007-06-14 | 2013-10-30 | Krka | Farmacevtski sestavki, ki obsegajo orlistat |
CN101224202A (zh) * | 2007-12-26 | 2008-07-23 | 广州康采恩医药有限公司 | 减肥组合物 |
-
2009
- 2009-09-18 MX MX2009009971A patent/MX342962B/es active IP Right Grant
-
2010
- 2010-09-13 BR BR112012006013A patent/BR112012006013A2/pt not_active Application Discontinuation
- 2010-09-13 EP EP10816760.2A patent/EP2478902A4/en not_active Withdrawn
- 2010-09-13 WO PCT/IB2010/002270 patent/WO2011033356A1/es active Application Filing
- 2010-09-16 AR ARP100103388A patent/AR078185A1/es unknown
-
2012
- 2012-03-16 GT GT201200079A patent/GT201200079A/es unknown
- 2012-04-13 CO CO12060999A patent/CO6541522A2/es unknown
- 2012-04-16 EC ECSP12011800 patent/ECSP12011800A/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998034607A1 (en) | 1997-02-05 | 1998-08-13 | F. Hoffmann-La Roche Ag | Tetrahydrolipstatin containing compositions |
WO2003009840A1 (en) * | 2001-07-24 | 2003-02-06 | Lonza Ag | Composition comprising at least one lipase inhibitor and carnitine |
WO2008082373A2 (en) * | 2006-12-29 | 2008-07-10 | Nobel Ilac San. Ve Tic. A.S. | Pharmaceutical formulations comprising lipase inhibitor |
Non-Patent Citations (4)
Title |
---|
DE DEROSA G; CICERO AG; GADDI A; MUGELLINI A; CICCARELLI L; FOGARI R: "The Effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus", CILN THER ., vol. 25, no. 5, 2003, pages 1429 - 39 |
ELMSLIE JL; PORTER RJ; JOYCE PR; HUNT PJ; MANN JL: "Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet", BIPOLAR DISORD, vol. 8, 2006, pages 503 - 507 |
I. LQFGREN; T ZERN; K.HERROM; K.WEST; M SHARMAN; J. VOLEK; N.SCHACHTER; S.KOO; M FERNANDEZ: "Weight loss associated with reduced intake of carbohydrate reduces the atherogenicity of LDL in premenopausal women", METABOLISM, vol. 54, no. 9, pages 1133 - 1141, XP005042456 |
See also references of EP2478902A4 * |
Also Published As
Publication number | Publication date |
---|---|
ECSP12011800A (es) | 2012-05-30 |
MX342962B (es) | 2016-06-07 |
CO6541522A2 (es) | 2012-10-16 |
EP2478902A4 (en) | 2014-05-14 |
AR078185A1 (es) | 2011-10-19 |
EP2478902A1 (en) | 2012-07-25 |
MX2009009971A (es) | 2011-03-18 |
BR112012006013A2 (pt) | 2016-06-14 |
GT201200079A (es) | 2014-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2352957T3 (es) | Composiciones orales para la absorción de compuestos de fósforo. | |
JP6550370B2 (ja) | 脂質レベルを低下させるロイシンおよびニコチン酸 | |
ES2606041T3 (es) | Composición de baja dosis de topiramato/fentermina y métodos de uso de la misma | |
ES2242413T3 (es) | Composiciones farmaceuticas que contienen inhibidores de lipasa. | |
ES2641889T3 (es) | Formulaciones de diclofenaco y métodos de uso | |
KR101303325B1 (ko) | 오셀타미버 포스페이트 과립 및 그의 제조방법 | |
ES2713330T3 (es) | Comprimido recubierto en seco que se desintegra oralmente | |
US8968768B2 (en) | Phytosterol nutritional supplements | |
BRPI0820308B1 (pt) | Composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido | |
ES2324670T3 (es) | Composicion farmaceutica que contiene fenofibrato y procedimiento para su preparacion. | |
ES2278314T3 (es) | Formulaciones orales para la liberacion controlada de la betaina. | |
JP2019023244A (ja) | 硫酸塩の両用経口薬学的組成物錠剤およびその使用の方法 | |
ES2230889T3 (es) | Acetaminofeno de liberacion prolongada. | |
ES2884973T3 (es) | Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD) | |
US20070190153A1 (en) | Delivery systems for non-steroidal anti-inflammatory drugs (nsaids) | |
WO2011033356A1 (es) | Composición farmacéutica para bajar de peso y procedimiento para obtener la misma | |
ES2763321T3 (es) | Premezcla y composición farmacéutica para la administración oral de memantina como una suspensión permanente o de preparación previa a la administración al paciente, optativamente por sonda de alimentación enteral y procedimientos correspondientes | |
WO2020208398A1 (es) | Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer | |
RU2166937C1 (ru) | Лекарственное средство на основе парацетамола | |
CN102526014A (zh) | 改良的磷酸奥司他韦药物组合物 | |
CN106580886A (zh) | 一种双氯芬酸钾散剂及其制备方法 | |
US20090209487A1 (en) | Compositions of carbohydrates as dietary supplements | |
ES2422877A2 (es) | Combinación y composición para el tratamiento de obesidad | |
JP4105732B2 (ja) | メニエール病治療薬 | |
JP2010174028A (ja) | 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10816760 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 000321-2012 Country of ref document: PE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12060999 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010816760 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012006013 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012006013 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120316 |